- Trials with a EudraCT protocol (1,315)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,315 result(s) found for: Lifestyle.
Displaying page 66 of 66.
EudraCT Number: 2011-001790-41 | Sponsor Protocol Number: AB11002 | Start Date*: 2013-04-10 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti... | |||||||||||||
Medical condition: Gastrointestinal stromal tumor resistant to imatinib | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001980-19 | Sponsor Protocol Number: 42756493BLC2002 | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically... | |||||||||||||
Medical condition: Metastatic or Surgically Unresectable Urothelial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004511-31 | Sponsor Protocol Number: cASPerCF_2007_OPBG_2019 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bambino Gesù Children's Hospital | |||||||||||||
Full Title: Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. | |||||||||||||
Medical condition: Cystic Fibrosis and Aspergillus Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) FR (Prematurely Ended) NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004984-35 | Sponsor Protocol Number: EZH-501 | Start Date*: 2016-08-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Subjects will receive tazemetostat as dictated in their antecedent study. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001698-25 | Sponsor Protocol Number: LIVERHOPE_EFFICACY | Start Date*: 2018-07-24 | |||||||||||
Sponsor Name:IDIBAPS | |||||||||||||
Full Title: Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical t... | |||||||||||||
Medical condition: Patients with decompensated cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001476-11 | Sponsor Protocol Number: AL002-2 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Early Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000367-83 | Sponsor Protocol Number: ENGOT-Cx10/GEICO68-C/BEATcc | Start Date*: 2018-08-08 | |||||||||||
Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO) | |||||||||||||
Full Title: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persi... | |||||||||||||
Medical condition: Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001148-67 | Sponsor Protocol Number: PB-102-F60 | Start Date*: 2018-09-26 | |||||||||||
Sponsor Name:Protalix Ltd. | |||||||||||||
Full Title: Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NO (Completed) CZ (Completed) ES (Ongoing) SI (Completed) NL (Completed) HU (Completed) IT (Completed) FI (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021091-28 | Sponsor Protocol Number: AB10004 | Start Date*: 2014-12-18 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination... | |||||||||||||
Medical condition: Relapsed or refractory Peripheral T-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GR (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) SK (Prohibited by CA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003582-28 | Sponsor Protocol Number: LOXO-TRK-15002 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) IE (Completed) ES (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) BE (Completed) CZ (Completed) SK (Completed) NO (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001511-73 | Sponsor Protocol Number: WA40404 | Start Date*: 2019-12-23 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | ||
Medical condition: | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001576-11 | Sponsor Protocol Number: 4010-03-001 | Start Date*: 2019-09-10 | ||||||||||||||||
Sponsor Name:TESARO, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced... | ||||||||||||||||||
Medical condition: Recurrent or primary advanced (Stage III or IV) endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017918-69 | Sponsor Protocol Number: AB08026 | Start Date*: 2011-01-14 | ||||||||||||||||
Sponsor Name:AB Science | ||||||||||||||||||
Full Title: A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the trea... | ||||||||||||||||||
Medical condition: Mélanome non-opérable ou métastasé de stade 3 ou de stade 4, portant une mutation dans le domaine juxta-membranaire de c-kit | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) SK (Prematurely Ended) DE (Prohibited by CA) CZ (Completed) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) IT (Prohibited by CA) GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000973-40 | Sponsor Protocol Number: AB04030 | Start Date*: 2008-12-18 | |||||||||||
Sponsor Name:AB SCIENCE | |||||||||||||
Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in... | |||||||||||||
Medical condition: gastro-intestinal stromal tumour | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Prohibited by CA) AT (Completed) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003688-25 | Sponsor Protocol Number: INS1007-301 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros... | |||||||||||||
Medical condition: Non-Cystic Fibrosis Bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
